Boehringer's Giotrif to get survival benefit on EU label; BMS sells Ixempra rights; No CV trial necessary for Esperion cholesterol med;

> European regulators recommended a label update for Boehringer Ingelheim's lung cancer drug Giotrif to cite a one-year overall survival benefit in a study in patients with a certain EGFR mutation, compared with chemotherapy. Release

> R-Pharma US bought the rights to Bristol-Myers Squibb's ($BMY) breast cancer treatment Ixempra and launched U.S. commercial operations to handle the drug. Report

> The FDA decided not to require a cardiovascular outcomes trial on Esperion Therapeutics' anti-cholesterol drug ETC-1002, a drug that could eventually compete with the forthcoming PCSK9 drugs. Report

> Kantar Health teamed up with Data2Life to flag early signals on drug side effects, based on data gleaned from a variety of real-world sources. Release

> Concordia Pharmaceuticals and Par Pharmaceutical settled charges of anti-competitive behavior leveled by the Federal Trade Commission, over an agreement not to compete sell rival generic versions of the ADHD drug Kapvay. Report

> Merck & Co. recalled 276,000 bottles of its chemotherapy drug branded and generic Temodar over cracks in child-proof caps. Report

A naloxone-dispensing clinic in Northern Kentucky helped change people's minds in favor of providing the opioid-overdose drug. Report

And Finally... Anthem issued a reminder to Medicare patients to switch to 90-day prescriptions in a move to boost adherence. Report